CN Stock MarketDetailed Quotes

Chengdu Kanghua Biological Products (300841)

Watchlist
  • 75.66
  • +0.16+0.21%
Market Closed Jan 16 15:00 CST
9.83BMarket Cap54.04P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Chengdu Kanghua Biological Products (300841) Revenue Breakdown Overview

By Product

Currency:CNY
2025/H1
Stock NameRevenueRatio
非免疫规划疫苗483.89M99.99%
Other business27.04K0.01%

By Industry

Currency:CNY
2024/FY
Stock NameRevenueRatio
Biological products1.33B92.59%
Other106.14M7.41%

By Country/Region

Currency:CNY
2025/H1
Stock NameRevenueRatio
East China219.08M45.27%
Central China75.9M15.68%
South China58.52M12.09%
Southwest52.34M10.82%
North China49.11M10.15%
Northwest21M4.34%
Northeast China7.96M1.64%
View all

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
HK Tech and Internet Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +17.85%
Sample Name
Sample Code
 +16.38%
Sample Name
Sample Code
 +13.45%
4
BIDU-SW
09888
+5.97%
5
JD HEALTH
06618
+5.25%
View More
Nancy Pelosi Portfolio
No. Symbol % Chg
Sample Name
Sample Code
 +7.11%
Sample Name
Sample Code
 +3.77%
Sample Name
Sample Code
 +2.24%
4
Broadcom
AVGO
+1.15%
5
Microsoft
MSFT
+1.05%
Will the 'tariff stick' strike again? Will the market remain 'reactive'?
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -